GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » T2 Biosystems Inc (NAS:TTOO) » Definitions » ROC (Joel Greenblatt) %

T2 Biosystems (T2 Biosystems) ROC (Joel Greenblatt) % : -389.73% (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is T2 Biosystems ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. T2 Biosystems's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -389.73%.

The historical rank and industry rank for T2 Biosystems's ROC (Joel Greenblatt) % or its related term are showing as below:

TTOO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1581.69   Med: -435.9   Max: -247.66
Current: -383.98

During the past 12 years, T2 Biosystems's highest ROC (Joel Greenblatt) % was -247.66%. The lowest was -1581.69%. And the median was -435.90%.

TTOO's ROC (Joel Greenblatt) % is ranked worse than
81.55% of 233 companies
in the Medical Diagnostics & Research industry
Industry Median: -13.95 vs TTOO: -383.98

T2 Biosystems's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 8.30% per year.


T2 Biosystems ROC (Joel Greenblatt) % Historical Data

The historical data trend for T2 Biosystems's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

T2 Biosystems ROC (Joel Greenblatt) % Chart

T2 Biosystems Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -625.39 -308.57 -247.66 -377.73 -396.21

T2 Biosystems Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -250.98 -491.77 -148.56 -509.81 -389.73

Competitive Comparison of T2 Biosystems's ROC (Joel Greenblatt) %

For the Diagnostics & Research subindustry, T2 Biosystems's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


T2 Biosystems's ROC (Joel Greenblatt) % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, T2 Biosystems's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where T2 Biosystems's ROC (Joel Greenblatt) % falls into.



T2 Biosystems ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1.139 + 4.281 + 3.137) - (10.905 + 0.276 + 1.82)
=-4.444

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1.42 + 4.819 + 3.261) - (11.239 + 0.224 + 1.789)
=-3.752

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of T2 Biosystems for the quarter that ended in Dec. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-36.716/( ( (9.789 + max(-4.444, 0)) + (9.053 + max(-3.752, 0)) )/ 2 )
=-36.716/( ( 9.789 + 9.053 )/ 2 )
=-36.716/9.421
=-389.73 %

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


T2 Biosystems  (NAS:TTOO) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


T2 Biosystems ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of T2 Biosystems's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


T2 Biosystems (T2 Biosystems) Business Description

Traded in Other Exchanges
Address
101 Hartwell Avenue, Lexington, MA, USA, 02421
T2 Biosystems Inc provides rapid in vitro diagnostic tests to hospitals and laboratories. The company's core technology is T2 Magnetic Resonance (T2MR) technology, which can detect a variety of molecular targets directly from whole blood. T2MR technology enables the T2Dx system, which is fully automated from patient sample to result for its panels focused on bacterial and fungal infections that could cause sepsis, and its pipeline panel for Lyme disease.
Executives
Cr Group L.p. 10 percent owner 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii - Parallel Fund (a) L.p. 10 percent owner C/O CAPITAL ROYALTY L.P., 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii L.p. 10 percent owner 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii - Parallel Fund B (cayman) L.p. 10 percent owner 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii (cayman) Lev Aiv I L.p. 10 percent owner 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii (cayman) Unlev Aiv I L.p. 10 percent owner 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Michael Terrence Gibbs officer: General Counsel 12 STONEY BROOK RD., HOPKINTON MA 01748
John M Sprague officer: Chief Financial Officer 101 HARTWELL AVE., LEXINGTON MA 02421
Sperzel John J Iii director, officer: See Remarks 61 CRESTVIEW LANE, BRUNSWICK ME 04011
Brett A. Giffin officer: Chief Commercial Officer 101 HARTWELL AVE., LEXINGTON MA 02421
Alec Barclay officer: SVP, Operations 101 HARTWELL AVE., LEXINGTON MA 02421
Aparna Ahuja officer: Chief Medical Officer 101 HARTWELL AVENUE, LEXINGTON MA 02421
Laura Lee Adams director 101 HARTWELL AVE., LEXINGTON MA 02421
Anthony Pare officer: Chief Commercial Officer HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Thierry Bernard director 101 HARTWELL AVENUE, LEXINGTON MA 02421